Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders characterized by inflammation and fibrosis of the lung parenchyma. These conditions, often progressive and potentially fatal, pose significant diagnostic and therapeutic challenges to healthcare professionals.
The pathophysiology of ILDs is complex and multifactorial, involving genetic predisposition, environmental exposures, and aberrant wound healing responses. These factors lead to alveolar epithelial injury, recruitment of inflammatory cells, and deposition of extracellular matrix, resulting in lung fibrosis and architectural distortion.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, revealing characteristic patterns such as reticular abnormalities, honeycombing, and ground-glass opacities. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management of ILDs is complex and often necessitates a multidisciplinary approach. Corticosteroids and immunosuppressants form the cornerstone of treatment for many ILDs. However, for idiopathic pulmonary fibrosis, the most common ILD, antifibrotic agents such as pirfenidone and nintedanib have shown benefit. Lung transplantation may be considered in severe cases.
The prognosis of ILDs varies widely, with median survival times ranging from 3 to 10 years depending on the specific ILD subtype. Early recognition and appropriate management can significantly improve patient outcomes. As healthcare professionals, understanding the complexities of ILDs is crucial to provide optimal care for these patients.
Interstitial lung diseases are a diverse group of disorders with significant morbidity and mortality. A thorough understanding of their pathophysiology, clinical presentation, diagnostic strategies, and management options is essential for healthcare professionals to effectively care for patients with these challenging conditions.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation